WT1 and glomerulosclerosis: Importantly, the results confirmed the therapeutic benefit of sparsentan on preserving p57+ (12.46 ± 0.57 vs. 4.37 ± 0.56 in control; Figure 6A) and WT1+ podocyte number (19.46 ± 0.35 vs. 7.02 ± 0.19 in control; Figure 6B) and reducing glomerulosclerosis (47.17 ± 3.20 vs. 101.70 ± 7.15 AU in control) and tissue fibrosis (36.30 ± 1.77 vs. 86.23 ± 4.42 AU in control; Figure 6C).